Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Adoptive cellular immunotherapy for viral diseases

Bone Marrow Transplantation volume 41, pages 193–198 (2008)Cite this article

Abstract

Viral infections remain a major cause of morbidity and mortality after pediatric hematopoietic stem cell transplantation. Adoptive transfer of donor-derived virus-specific T cells can reconstitute antiviral immunity in recipients and be effective both in preventing and treating cytomegalovirus, Epstein–Barr virus and adenovirus infection. Current efforts are focused on providing protection toward a broader range of viruses safely, rapidly and effectively.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J . Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543–558.

    Article  Google Scholar 

  2. Young LS, Rickinson AB . Epstein–Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757–768.

    Article  CAS  Google Scholar 

  3. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–2216.

    CAS  PubMed  Google Scholar 

  4. Cohen JM, Cooper N, Chakrabarti S, Thomson K, Samarasinghe S, Cubitt D et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007; 48: 256–269.

    Article  Google Scholar 

  5. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA et al. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874–2880.

    Article  CAS  Google Scholar 

  6. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502–1505.

    CAS  PubMed  Google Scholar 

  7. Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007; 7: 1648–1655.

    Article  CAS  Google Scholar 

  8. Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005; 36: 1001–1008.

    Article  CAS  Google Scholar 

  9. Feuchtinger T, Lucke J, Hamprecht K, Richard C, Handgretinger R, Schumm M et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2005; 128: 503–509.

    Article  Google Scholar 

  10. Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE et al. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 677–686.

    Article  CAS  Google Scholar 

  11. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232–1240.

    Article  CAS  Google Scholar 

  12. Gottschalk S, Rooney CM, Heslop HE . Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29–44.

    Article  CAS  Google Scholar 

  13. Gillespie GM, Wills MR, Appay V, O'Callaghan C, Murphy M, Smith N et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000; 74: 8140–8150.

    Article  CAS  Google Scholar 

  14. Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999; 162: 1827–1835.

    CAS  PubMed  Google Scholar 

  15. Papadopoulos EB, Ladanyi M, Emanuel D, MacKinnon S, Boulad F, Carabasi MH et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185–1191.

    Article  CAS  Google Scholar 

  16. Hromas R, Cornetta K, Srour E, Blanke C, Broun ER . Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994; 84: 1689–1690.

    CAS  PubMed  Google Scholar 

  17. Heslop HE, Brenner MK, Rooney CM . Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994; 331: 679–680.

    Article  CAS  Google Scholar 

  18. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007; 109: 4698–4707.

    Article  CAS  Google Scholar 

  19. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247–4254.

    Article  CAS  Google Scholar 

  20. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360: 130–137.

    Article  Google Scholar 

  21. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108: 1797–1808.

    Article  CAS  Google Scholar 

  22. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106: 1123–1129.

    Article  CAS  Google Scholar 

  23. Rooney CM, Smith CA, Ng CYC, Loftin SK, Sixbey JW, Gan Y-J et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549–1555.

    CAS  PubMed  Google Scholar 

  24. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807–814.

    CAS  PubMed  Google Scholar 

  25. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA et al. Semiquantitative Epstein–Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654–3661.

    CAS  PubMed  Google Scholar 

  26. Imashuku S, Goto T, Matsumura T, Naya M, Yamori M, Hojo M et al. Unsuccessful CTL transfusion in a case of post-BMT Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant 1998; 20: 337–340.

    Article  Google Scholar 

  27. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123–1131.

    Article  CAS  Google Scholar 

  28. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038–1044.

    Article  CAS  Google Scholar 

  29. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916–3922.

    Article  CAS  Google Scholar 

  30. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375–1377.

    Article  Google Scholar 

  31. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379–386.

    Article  CAS  Google Scholar 

  32. Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 707–714.

    Article  CAS  Google Scholar 

  33. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64–76.

    Article  Google Scholar 

  34. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160–1166.

    Article  CAS  Google Scholar 

  35. Rooney CM, Smith CA, Ng C, Loftin SK, Li C, Krance RA et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr virus-related lymphoproliferation. Lancet 1995; 345: 9–13.

    Article  CAS  Google Scholar 

  36. Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551–555.

    Article  CAS  Google Scholar 

  37. Gottschalk S, Ng CYC, Smith CA, Perez M, Sample C, Brenner MK et al. An Epstein–Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 2001; 97: 835–843.

    Article  CAS  Google Scholar 

  38. Gandhi MK, Wilkie GM, Dua U, Mollee PN, Grimmett K, Williams T et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007; 7: 1293–1299.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH Grants PO1 CA94237, U54HL081007, the GCRC at Baylor College of Medicine (RR00188), and a Specialized Center of Research Award from the Leukemia Lymphoma Society, and a Doris Duke Distinguished Clinical Scientist Award to HEH.

Author information

Authors and Affiliations

  1. Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA

    Y Fujita, C M Rooney & H E Heslop

Authors
  1. Y Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C M Rooney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H E Heslop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H E Heslop.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujita, Y., Rooney, C. & Heslop, H. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant 41, 193–198 (2008). https://doi.org/10.1038/sj.bmt.1705906

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705906

Keywords

This article is cited by

Search

Advanced search

Quick links